Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV1 in COPD patients

Medical Science Monitor

Volumn 19, Issue , 2013, Pages 1229-1235

  Huang, Cuiping ^a   Xie, Moying ^a   He, Xinhua ^a   Gao, Hui ^a  

^a HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chronic obstructive pulmonary disease; CXCL8; P38 mitogen activated protein kinase

Indexed keywords

ACTIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; NEUTROPHIL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; WESTERN BLOTTING;

BLOTTING, WESTERN; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; INTERLEUKIN-8; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 84891865062     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889880     Document Type: Article

References (48)

1. Lopez AD, Shibuya K, Rao C et al: Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J, 2006; 27: 397-412
2. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 2006; 3: e442
3. Weiss ST: Lung function and airway diseases. Nat Genet, 2010; 42: 14-16
4. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, MD: National Heart, Lung and Blood Institute, 2009
5. Hogg JC, Chu F, Utokaparch S, Woods R et al: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 2004; 350: 2645-53
6. Gorska K, Maskey-Warzechowska M, Krenke R: Airway inflammation in chronic obstructive pulmonary disease. Curr Opin Pulm Med, 2010; 16: 89-96
7. Mukaida N: Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol, 2003; 284: L566-77
8. Matsushima K, Morishita K, Yoshimura T et al: Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med, 1988; 167: 1883-93
9. Van Damme J, Rampart M, Conings R et al: The neutrophil-activating proteins interleukin 8 and beta-thromboglobulin: in vitro and in vivo comparison of NH2-terminally processed forms. Eur J Immunol, 1990; 20: 2113-18
10. Mukaida N: Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol, 2000; 72: 391-98
11. Kunz M, Hartmann A, Flory E et al: Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol, 1999; 155: 753-63
12. Holmes WE, Lee J, Kuang WJ et al: Structure and functional expression of a human interleukin-8 receptor. Science, 1991; 253: 1278-80
13. Murphy PM, Tiffany HL: Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science, 1991; 253: 1280-83
14. Servant G, Weiner OD, Herzmark P et al: Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science, 2000; 287: 1037-40
15. Hirsch E, Katanaev VL, Garlanda C et al: Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science, 2000; 287: 1049-53
16. Barnes PJ: New therapies for chronic obstructive pulmonary disease. Med Princ Pract, 2010; 19: 330-38
17. Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest, 2011; 139: 1470-79
18. Renda T, Baraldo S, Pelaia G et al: Increased activation of p38 MAPK in COPD. Eur Respir J, 2008; 31: 62-69
19. Smith SJ, Fenwick PS, Nicholson AG et al: Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol, 2006; 149: 393-404
20. Medicherla S, Fitzgerald MF, Spicer D et al: p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther, 2008; 324: 921-29
21. Brightling CE, Ward R, Goh KL et al: Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med, 1999; 160: 406-10
22. Bie B, Brown DL, Naguib M: Increased synaptic GluR1 subunits in the anterior cingulate cortex of rats with peripheral inflammation. Eur J Pharmacol, 2011; 653: 26-31
23. Bie B, Zhang Z, Cai Y-Q et al: Nerve Growth Factor-Regulated Emergence of Functional delta-Opioid Receptors. J Neurosci, 2010; 30: 5617-28
24. Clark AK, Staniland AA, Marchand F et al: P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci, 2010; 30: 573-82
25. Han MK, Agusti A, Calverley PM et al: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med, 2010; 182: 598-604
26. Moretto N, Facchinetti F, Southworth T et al: alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. Am J Physiol Lung Cell Mol Physiol, 2009; 296: L839-48
27. Tsai WC, Strieter RM, Wilkowski JM et al: Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice. J Immunol, 1998; 161: 2435-40
28. Djeu JY, Matsushima K, Oppenheim JJ et al: Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. J Immunol, 1990; 144: 2205-10
29. Aggarwal A, Baker CS, Evans TW, Haslam PL: G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J, 2000; 15: 895-901
30. Fujimura M, Myou S, Nomura M et al: Interleukin-8 inhalation directly provokes bronchoconstriction in guinea pigs. Allergy, 1999; 54: 386-91
31. Lamblin C, Gosset P, Tillie-Leblond I et al: Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med, 1998; 157: 394-402
32. Kurashima K, Mukaida N, Fujimura M et al: Increase of chemokine levels in sputum precedes exacerbation of acute asthma attacks. J Leukoc Biol, 1996; 59: 313-16
33. Car BD, Meloni F, Luisetti M et al: Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med, 1994; 149: 655-59
34. Hill AT, Bayley D, Stockley RA: The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med, 1999; 160: 893-98
35. Yamamoto C, Yoneda T, Yoshikawa M et al: Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest, 1997; 112: 505-10
36. Singh D, Edwards L, Tal-Singer R, Rennard S: Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res, 2010; 11: 77
37. Liao Y, Wang X, Huang M et al: Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus. Virology, 2011; 420: 106-16
38. Bezzerri V, Borgatti M, Finotti A et al; Mapping the transcriptional machinery of the IL-8 gene in human bronchial epithelial cells. J Immunol, 2011; 187: 6069-81
39. Sarir H, Mortaz E, Karimi K et al: Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages. J Inflamm (Lond), 2009; 6: 12
40. Corhay JL, Henket M, Nguyen D et al: Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest, 2009; 136: 1047-54
41. Chen Y, Zhao Y, Wang C et al: Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells. Med Sci Monit, 2012; 18(10): BR383-88
42. Singh D, Smyth L, Borrill Z et al: A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol, 2010; 50: 94-100
43. Underwood DC, Osborn RR, Bochnowicz S et al: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol, 2000; 279: L895-902
44. Underwood DC, Osborn RR, Kotzer CJ et al: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther, 2000; 293: 281-88
45. Adcock IM, Chung KF, Caramori G, Ito K: Kinase inhibitors and airway inflammation. Eur J Pharmacol, 2006; 533: 118-32
46. Novikov KN, Berdnikova NG, Novikov AK et al: Changes in chemiluminescence of whole blood of COPD patients treated with Hypoxen and effects of C(6)(0) fullerenes on blood chemiluminescence. Med Sci Monit, 2012; 18(2): BR76-83
47. Rabe KF, Hurd S, Anzueto A et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007; 176: 532-55
48. Lomas DA, Lipson DA, Miller BE et al: An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. J Clin Pharmacol, 2012; 52(3): 416-24